clinical research organization in french

You are using an outdated browser. Please upgrade your browser to improve your experience.

Direct access to content
Direct access to Main Menu
Direct access to Search Form

Inserm is the only public research organization in France entirely dedicated to human health. Its objective is to promote the health of all by advancing knowledge about life and disease, treatment innovation, and public health research.

Find here all the information about the Institute.

Direct access to our strategic documents (Activity Report, Strategic Plan...)

Research Programs

Through its research programs, Inserm aims to facilitate and accelerate discoveries and their transformation into tangible progress for patients and society. In this sense, the Institute is developing a research environment that is conducive to interactions between basic, translational, and clinical research. Inserm is also participating in the steering and implementation of France’s national health research […]

Published on: 02/07/2021
Modified on: 07/11/2024
Category: About Us

ATIP-Avenir Program

Established as part of a partnership between Inserm and CNRS, each year the ATIP-Avenir program facilitates the creation of research teams in the fields of life sciences and health for approximately twenty young researchers. To date, this program has provided support to over 400 promising scientists. Created in 1990 and 2000 respectively, and subsequently merged in […]

Modified on: 16/09/2024

clinical research organization in french

Strategic documents

Annual activity reports, financial and asset balance reports, strategic plan, objective-based contract... You’ll find on this page the strategic documents of Inserm. You can also access some of them in a leafable version on our Calameo channel. Annual Report Strategic Plan and Objective-based Contract Plan for Professional Equality between Women and Men at Inserm Inserm Evaluation […]

Published on: 12/07/2021
Modified on: 01/07/2024

Governance and organization

The National Institute of Health and Medical Research (Inserm) has research facilities throughout France. These report to Regional Offices and scientific divisions. National governance is by the Directorate General and the various bodies of Inserm, supported by the committees and cross-functional departments. Directorate General The Inserm Chairman and Chief Executive Officer is appointed by decree […]

Published on: 30/06/2021

Inserm at a Glance

Founded in 1964, Inserm is a public scientific and technological institute which operates under the joint authority of the French Ministries of Health and Research. The institute is dedicated to biomedical research and human health, and is involved in the entire range of activities from the laboratory to the patient’s bedside. It also partners with […]

Published on: 19/07/2017
Modified on: 16/05/2024

Inserm brings together 15,000 researchers, engineers, technicians and administrative staff, all with one shared objective: improve health by advancing knowledge about living organisms and diseases, developing innovative treatment modalities and conducting research on public health. Improve human health Since it was founded in 1964, Inserm has played an active role in major medical breakthroughs, including […]

Modified on: 05/02/2024

Research Partnerships

Inserm conducts its research in partnership with numerous players in France: higher education institutions, research organizations, university hospitals, health operators, industry, patient organizations and foundations, local authorities, health agencies, and social welfare organizations. These partnerships take the form of Joint Research Units (JRUs), set up as part of a strategy of shared scientific objectives. Inserm […]

Modified on: 01/02/2024

Technology Research Accelerators (ART)

Since 2015, Inserm has been developing programs that aim to accelerate technology research and provide its research teams with the most innovative technologies. Scientific research is increasingly dependent on access to cutting-edge technology. To provide itself with the capacity for innovation and technological development, and to translate technology into its laboratories, Inserm has developed its […]

Modified on: 22/05/2023

Échographie 2D ultrarapide © Inserm/Guénet, François

Inserm Prizes

By celebrating its talent, Inserm intends to showcase the diversity and abundance of the biomedical research professions and the creativity and passion of the people that keep things running every day. The 2023 winners The 2022 winners The 2021 winners Inserm Prizes The Grand Prize pays tribute to a French scientific research player whose work has led to […]

Modified on: 06/12/2022

Photo des lauréats des Prix Inserm 2023 : Nadine Cerf-Bensussan, Thomas Baumert, Alexandre Loupy, Marina Kvaskoff et Ghislaine Filliatreau

Inserm and Patient Organizations

Researchers on one side – patients and their relatives on the other? Fortunately, biomedical research no longer sees things this way! While patients need researchers to understand their diseases better and bring about advances in their care, researchers also need patients who are able to describe their illness, express their expectations, and actively participate in […]

Published on: 09/07/2021

Cookie settings

Connect with us

We are a human-sized consultancy and full-service CRO

providing a seamless solution with strategy, authorization, and commercialization for your innovation in Europe and internationally.

ClinSearch is a French Clinical Research Organization which provides clinical development and commercialization services for medical device and drug development on a European level. We are committed to offering individualized, cost-effective solutions to managing your pre- or post-marketing study in Europe, as well as obtaining reimbursement in key markets. From developing study methodology, to writing and reviewing study documents, conducting regulatory and site feasibility, adapted electronic data management solutions, monitoring in Europe, producing top-notch study and statistical reports : we have it all under our roof in Malakoff, South-West Paris. We have been serving the pharmaceutical and medical device industry since 1999, earning a reputation for delivering practical, measurable and high added-value data. A proud employer of 20 nationalities , with uncompromising focus on regulatory compliance and best industry practices, we are able to pull our agile team of cross-functional experts to overcome any challenge in the clinical development or reimbursement process. Our promise is to always give you realistic advice, brainstorm the best solutions for you, and stand behind our word in terms of timelines and budgeting . Our services are always evolving, recently branching out more into digital solutions for accelerated recruitment and the procurement of superior clinical and reimbursement data.

Brands & Services

Cécile Train MS

Senior Director Medical Device & Drug Development

Petra Ulm MS

Global Reg. Affairs Director, Data Protection Officer

Thibault Bogniaho MS

IS & IT Director, Chief Information Security Officer

ClinSearch News

“ClinSearch has just received a Letter of Support from the European Medicines Agency (EMA) for its Acceptability Score Test for oral medicines in children under 12 years of age...”

EUROPEAN MEDICINES AGENCY PUBLISHED A LETTER OF SUPPORT FOR OUR ACCEPTABILITY SCORE TEST

“ClinSearch is a top-notch organization. The team I have worked with is extremely skilled, accountable for their work, and easy to work with. Whenever there is a question or issue that needs to be addressed, I know that it will be taken care of in an expedited manner. The organization is a real pleasure to work and do business with.”

Director, Clinical Operations , Medical Device Start-up (USA)

“Clinsearch is a great partner to work with, with every team member being professional and efficient. They have a really proactive approach and propose actions when they foresee any risk on the projects. They are also highly reliable and committed to the established agreement. The Clinsearch team is very focused on what we ask them to do and excel at prioritizing.”

Clinical Programs Manager , Medical Device Multinational (France)

“We have been working with Clinsearch for nearly 10 years on Phase III and Phase IV clinical trials in the fields of immunology and emergency medicine with blood product derivatives. Clinsearch is really concerned with performing high-quality work in all clinical research steps, including results reports and publication. They are a reliable and professional partner that we strongly recommend!”

Medical Director , Pharma multinational (EMEA)

“I am very satisfied to be in business with competent professionals, who knew how to work swiftly in order to respect very tight deadlines.”

Inernational Clinical Program Manager , Pharma multinational (France)

March 20—22, 2024

51th Congress SFNR Paris, France

We'd love to talk about your business!

110, Avenue Pierre Brossolette 92240 — Malakoff
+ 33 (0) 1 47 35 17 17
[email protected]
clinsearch.net

Map of networks
New methodologies in clinical research
Organization
Dynamic map of networks
F-CRIN key figures
Expertise in clinical research
Pedagogical expertise
F-CRIN Network Incubator
Success stories
Involvement in clinical research
La mission en quelques lignes
Une mission conjointe AIS et F-CRIN
Les travaux AIS/F-CRIN en détail
Avancement des travaux
Archives des Newsletters

MUST Network

The F-CRIN Infrastructure has labelled the MUST (Multidisciplinary UniverSitary Research neTwork for Primary Care) network.

F-CRIN in brief

F-CRIN stands for “French Clinical Research Infrastructure Network” . It was set up in 2012 to study human health and diseases. Its main goals are to unlock synergies between French clinical research players by promoting scientific excellence and operational collaboration, and also to represent the European clinical research network – ECRIN-ERIC – in France.

Today, ten years after its founding, F-CRIN operates through an original organisational model of 22 components: 17 theme-based clinical research and investigation networks, 3 networks of advanced expertise, 1 multiservice platform and 1 national coordination unit acting as infrastructure headquarters. F-CRIN now covers over 19 medical fields.

of projects with an international scope

Research projects involving f-crin, of projects conducted with an industrial partners, publications mentioning f-crin or its components, f-crin coordination units across france.

F-CRIN, a national infrastructure with 21 components across France .

Infrastructure News

16 September 2024

3 questions to the MUST network

13 June 2024

Symposium "Next generation in clinical research: AI, in silico and external arms, Time to make them real" - June 24, 2024 in Lille (France)

04 October 2023

3rd CTU Day ECRIN - December 4, 2023

06 June 2023

Switzerland acquires ECRIN member status

16 May 2023

ECRIN welcomes its newest member: GREECE

20 April 2023

International Clinical Trials Day (ICTD) 2023: Decentralized Clinical Trials: Challenges and Opportunities

12 December 2022

Launch by F-CRIN of a new national digital platform for information on French clinical research training, the "Training Course Advisor", www.tca.fcrin.org.

Our partners.

A unique CRO

The CERC is a unique Contract Research Organization based in Massy, France, and presided by five medical directors, Marie-Claude Morice, Philip Urban, Philippe Garot, Davide Capodanno and Antoinette Neylon.

The CERC was conceived and founded by physicians with wide experience in clinical research. Their renown and expertise in this field have enabled them to generate optimal interaction with their industrial partners and other medical research teams focusing on the development of innovative techniques, concepts and treatments.

Prestigious members

The prestigious members of the CERC’s Medical Advisory Council provide unparalleled guidance and expert support in a broad range of clinical trials dedicated to the assessment of interventional coronary and peripheral revascularization, structural and valvular heart disease treatments and adjunctive pharmacology.

The CERC has an excellent track record in regulatory guidance, trial design, global study management and monitoring, CEC/DSMB coordination, core-lab activities for pre- and post- market drug and device trials.

Diversity and high quality

The CERC was created with the aim of establishing a reputable high-quality dedicated CRO in Europe. Its objectives are to underpin European clinical trials and academic leadership, act as a global CRO and support young scientific leaders.

The uniqueness of the CERC lies in the diversity of expertise, experience and geographic locations of its council members. This has been one of the CERC’s cornerstones on which it has built a strong partnership with start-up and major companies and prominent stakeholders in interventional cardiology.

The CERC’s industrial partners attach great importance to finding cost-effective models which do not compromise quality. The CERC has established a network with other CROs in order to achieve this objective.

The CERC is not structured as a pyramid, it is intended to operate in a star-shaped pattern.

The CERC organizes regular meetings with various companies in order to provide them with the opportunity of obtaining consistent, confidential and objective feedback from a group of interventional experts in the field of cardiovascular medicine.

Contract research organization in France

Interested in becoming a vendor.

REACH OUT TO [email protected] FOR MORE INFORMATION.

Participate in a study

For questions or assistance please email [email protected]

PLEASE CONTACT HR SUPPORT FOR ALL CAREER RELATED INQUIRIES.

Interested in becoming an investigator?

PLEASE CLICK HERE TO SUBMIT INQUIRY.

" * " indicates required fields

Your form has been successfully submitted!

We will respond to your inquiry as soon as possible.

Paris location

13-15 rue Taitbout, 75009, Paris cedex France

If you wish to participate in our clinical trials, please call +1 210-635-1515 or visit here .

Visit Careers to view and apply for all open jobs here.

View all Worldwide offices on our Global Reach page.

Contract research services in Paris

Worldwide Clinical Trials employs more than 2,000+ professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia, and Asia. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way.

From early phase and bioanalytical sciences through late phase, post-approval and real-world evidence, we provide world-class, full-service drug development services. With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, general medicine, oncology and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo.

Cookies on the Worldwide Clinical Trials website

We use cookies to improve your browsing experience and help us improve our websites. We have carefully selected third parties that use cookies to achieve purposes illustrated in the cookie policy. For more information. Read more about online privacy statement . By closing this banner or continuing to browse our website, you agree to our use of such cookies.

Connexion à votre compte

Forgot your password?
Forgot your username?
Create an account

Select your language

GCO, A French network of ten coperative groups conducting cancer clinical research

GCO (Groupes Coopérateurs en Oncologie) is a French network of ten cancer cooperative groups that conduct cancer clinical and translational research in France, and in Europe and in other countries. Most of these groups are organ specific (e.g., lung, digestive, gynecologic, lymphoma, myeloma, head and neck, and brain cancers).

Usually acting as study promotors and benefiting from their own operational resources, they have a strong track record of designing and completing trials that have diminished the impact of cancer in many ways. GCO also play a strong science dissemination role through numerous publications in leading medical journals and presentations at the main oncology congresses.

They are all not-for-profit organizations and have been accredited “French cooperative intergroup of international dimension in the field of cancer” by the French National Cancer Institute (INCa).

They are committed to respect principles relating to: - Statutory operating procedures and not-for-profit management - Academic communication of all research project results - Financial transparency Download the Ethics Charter of the GCO network

Collaboration between the cooperative groups and the pharmaceutical or biothechnological industries is a natural occurrence, with all parties sharing common goals: producing top-quality scientific results and developing effective, well-tolerated treatments. However, both cooperative groups and industry have to consider the potential divergences in their approaches to creating a partnership that is both effective and operates in a transparent manner. This requires the industry to respect certain principals essential to the success of cooperative groups, those which ensure both their independence and industrial confidence. Collaboration between these parties is distinctly different from a service-provider arrangement. It must therefore be formalized for each project, with terms laid out in a partnership convention. The Charter of collaboration between the Cancer Cooperative Groups and industry outlines the principals to be respected in order to establish such a partnership convention, which, once drawn up, will include the Charter as an annex.

ARCAGY GINECO: Cooperative Gynecological Cancer Research Group
FFCD: Francophone Federation of Digestive Tract Cancerology
CIGAL: The Cooperative Intergroup for Advances in Leukemia *
GERCOR: Oncology Multidisciplinary Research Group
GORTEC: French Head and Neck Oncology and Radiotherapy Group
IFCT: French Cooperative Thoracic Intergroup
LYSA: The Lymphoma Study Association
LYSARC: The Lymphoma Academic Research Organisation
IFM: Intergroup Francophone of Myeloma
ANOCEF - IGCNO: Cooperator Intergroup in Neurology and Oncology
SFCE: French Society for the Fight against Cancer and Leukemia in Children and Adolescents

* CIGAL, The Cooperative Intergroup for Advances in Leukemia, is an intergroupe made up of 5 cooperative groups : ALFA (Acute Leukemia French Association), FILO ( French Innovative Leukemia Organization ( FILO) , FIM ( French Intergroup of Myeloproliferative syndromes ), GFM (Francophone Group of Myelodysplasia), GRAALL (Group for Research on Adult Acute Lymphoblastic Leukemia.

GCO members

Carte dynamique des réseaux
La recherche clinique

Welcome to the FORCE network

Welcome to our new website. Discover the network via the Specialist Obesity Centres, the experts and all the latest news on obesity!

About FORCE

FORCE is the French national network of clinical research within the fields of nutrition, obesity and associated metabolic disorders, coordinated by Pr. Sébastien CZERNICHOW et Pr Emmanuel DISSE. As a member of F-CRIN , FORCE is recognized as a research centre of excellence by the French National Research Agency since 2014.By bringing together a large number of experts (clinicians, researchers and scientific partners), its main mission is to strengthen the performance of French clinical research within the fields of nutrition, obesity and metabolic disorders and its attractiveness at the European and international level.